KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

被引：2
|
作者：
Lee, Chung-Han
Li, Chenxiang
Perini, Rodolfo F.
Hoehn, Daniela
Albiges, Laurence
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4595
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
    Bryce R. Christensen
    Yasmin M. Hajja
    Vadim Koshkin
    Pedro C. Barata
    Current Treatment Options in Oncology, 2021, 22
  • [42] Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
    Christensen, Bryce R.
    Hajja, Yasmin M.
    Koshkin, Vadim
    Barata, Pedro C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (02)
  • [43] ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma
    Zhang, Hailiang
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases
    Matsumoto, Daisuke
    Naiki, Taku
    Naiki-Ito, Aya
    Aoki, Maria
    Kato, Shinji
    Morikawa, Toshiharu
    Shimizu, Nobuhiko
    Gonda, Masakazu
    Umemoto, Yukihiro
    Yasui, Takahiro
    IJU CASE REPORTS, 2025, 8 (01) : 5 - 9
  • [45] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial.
    Barata, Pedro C.
    Allman, Kim
    Asnis-Alibozek, Aviva G.
    Kasturi, Vijay
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Pazopanib for treatment of metastatic renal cell carcinoma with non-clear cell histology: Single-arm, open label, multicenter, phase II study.
    Jung, Ki Sun
    Cho, Jinhyun
    Yoo, Kwai Han
    Park, Se Hoon
    Lee, Jae-Lyun
    Lee, Se-Hoon
    Lim, Jae Yun
    Kang, Jung Hun
    Lee, Suee
    Rha, Sun Young
    Lee, Kyung Hee
    Kim, Ho Young
    Lim, Ho Yeong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [48] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Ran
    Bapat, Urmi
    Ye, Weifei
    Jain, Rohit K.
    Fishman, Mayer N.
    EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
  • [49] Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
    McDermott, David F.
    Lee, Jae-Lyun
    Szczylik, Cezary
    Donskov, Frede
    Malik, Jahangeer
    Alekseev, Boris Yakovlevich
    Larkin, James M. G.
    Matveev, Vsevolod Borisovich
    Gafanov, Rustem Airatovich
    Tomczak, Piotr
    Tykodi, Scott S.
    Geertsen, Poul F.
    Wiechno, Pawel J.
    Shin, Sang Joon
    Pouliot, Frederic
    Gordoa, Teresa Alonso
    Li, Wenting
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial
    Nguyen, Charles B.
    Vaishampayan, Ulka N.
    Campbell, Matthew T.
    Hammers, Hans J.
    Brooks, Roserika
    Solley, Travis
    Wood, Lauren Michelle
    Jonasch, Eric
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345